Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total value of $29,323.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Charles Dadswell also recently made the following trade(s):

  • On Tuesday, September 5th, Charles Dadswell sold 145 shares of Illumina stock. The stock was sold at an average price of $205.71, for a total value of $29,827.95.
  • On Thursday, August 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The stock was sold at an average price of $197.00, for a total value of $316,973.00.

Shares of Illumina, Inc. (NASDAQ ILMN) remained flat at $205.78 during mid-day trading on Thursday. The company had a trading volume of 494,189 shares. The stock has a market capitalization of $30.04 billion, a price-to-earnings ratio of 41.29 and a beta of 0.76. The stock has a 50 day moving average price of $201.87 and a 200-day moving average price of $183.93. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $214.34.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.14. The company had revenue of $662.00 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. Illumina’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 earnings per share. On average, equities research analysts predict that Illumina, Inc. will post $3.65 earnings per share for the current year.

WARNING: “Charles Dadswell Sells 145 Shares of Illumina, Inc. (ILMN) Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/05/charles-dadswell-sells-145-shares-of-illumina-inc-ilmn-stock.html.

A number of equities research analysts recently commented on ILMN shares. Deutsche Bank AG set a $175.00 target price on Illumina and gave the stock a “hold” rating in a report on Friday, July 28th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and lifted their target price for the stock from $170.00 to $215.00 in a report on Monday, August 7th. Morgan Stanley reaffirmed an “underweight” rating and set a $122.00 target price (up previously from $115.00) on shares of Illumina in a report on Monday, July 10th. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a report on Wednesday, June 21st. Finally, Barclays PLC reaffirmed a “hold” rating and set a $150.00 target price on shares of Illumina in a report on Wednesday, July 19th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $183.00.

A number of institutional investors have recently added to or reduced their stakes in the business. First Citizens Bank & Trust Co. increased its position in Illumina by 0.4% during the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock worth $536,000 after buying an additional 12 shares in the last quarter. Patten Group Inc. grew its position in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares during the period. Puzo Michael J grew its position in shares of Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after purchasing an additional 25 shares during the period. Flagship Harbor Advisors LLC grew its position in shares of Illumina by 1.7% in the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after purchasing an additional 35 shares during the period. Finally, Eqis Capital Management Inc. grew its position in shares of Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after purchasing an additional 38 shares during the period. 93.32% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.